← All trials
NCT05089656
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2021
- Primary completion
- Jul 15, 2024
- Completion date
- Oct 4, 2024
- First posted
- Oct 22, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 125
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NovartisLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.